These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 3340061)

  • 21. Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma.
    Abali H; Urün Y; Oksüzoğlu B; Budakoğlu B; Yildirim N; Güler T; Ozet G; Zengin N
    Cancer Invest; 2008 May; 26(4):401-6. PubMed ID: 18443961
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cisplatin and ifosfamide with either vinblastine or etoposide as salvage therapy for refractory or relapsing germ cell tumor patients: the Institut Gustave Roussy experience.
    Farhat F; Culine S; Théodore C; Békradda M; Terrier-Lacombe MJ; Droz JP
    Cancer; 1996 Mar; 77(6):1193-7. PubMed ID: 8635143
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Salvage chemotherapy in refractory germ cell tumors with etoposide (VP-16) plus ifosfamide plus high-dose cisplatin. A VIhP regimen.
    Ghosn M; Droz JP; Theodore C; Pico JL; Baume D; Spielmann M; Ostronoff M; Moran A; Salloum E; Kramar A
    Cancer; 1988 Jul; 62(1):24-7. PubMed ID: 3133101
    [TBL] [Abstract][Full Text] [Related]  

  • 24. VP 16 plus ifosfamide plus cisplatin as salvage therapy in refractory testicular cancer.
    Einhorn LH
    Cancer Chemother Pharmacol; 1986; 18 Suppl 2():S45-50. PubMed ID: 3815718
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Salvage chemotherapy with a combination of VP-16, ifosfamide, procarbazine, prednisolone, bleomycin and methotrexate (VIPP-BM) for refractory malignant lymphoma].
    Ohnishi K; Hotta T; Murate T; Inoue C; Ichikawa A; Ninomiya N; Goto S; Tsushita K; Utsumi M; Nagura E
    Rinsho Ketsueki; 1989 Mar; 30(3):289-96. PubMed ID: 2475652
    [TBL] [Abstract][Full Text] [Related]  

  • 26. European experience with ifosfamide in non-small cell lung cancer.
    Drings P
    Semin Oncol; 1989 Feb; 16(1 Suppl 3):22-30. PubMed ID: 2539645
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase II study of cisplatin, ifosfamide with mesna, and etoposide (PIE) chemotherapy for advanced non-small cell lung cancer.
    Shirinian M; Lee JS; Dhingra HH; Greenberg J; Hong WK
    Semin Oncol; 1992 Feb; 19(1 Suppl 1):49-53. PubMed ID: 1329212
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neoadjuvant etoposide, ifosfamide, and cisplatin followed by concomitant thoracic radiotherapy and continuous cisplatin infusion in stage IIIb non-small cell lung cancer.
    Pujol JL; Lafontaine T; Quantin X; Reme-Saumon M; Cupissol D; Khial F; Michel FB
    Chest; 1999 Jan; 115(1):144-50. PubMed ID: 9925076
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A phase II study of VP-16-fosfamide-cisplatin combination chemotherapy plus early concurrent thoracic irradiation for previously untreated limited small cell lung cancer.
    Woo IS; Park YS; Kwon SH; Park YL; Lee JA; Park MJ; Hyun IG; Jung KS; Bae HS; Oh DH; Kim WS; Park K; Park CH; Kim HJ; Ahn YC
    Jpn J Clin Oncol; 2000 Dec; 30(12):542-6. PubMed ID: 11210163
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Results of recent salvage chemotherapy regimens for lymphoma and Hodgkin's disease.
    Cabanillas F; Velasquez WS; McLaughlin P; Jagannath S; Hagemeister FB; Redman JR; Swan F; Rodriguez MA
    Semin Hematol; 1988 Apr; 25(2 Suppl 2):47-50. PubMed ID: 3041599
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma: an intergroup trial.
    Loehrer PJ; Jiroutek M; Aisner S; Aisner J; Green M; Thomas CR; Livingston R; Johnson DH
    Cancer; 2001 Jun; 91(11):2010-5. PubMed ID: 11391579
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sequential intermediate high-dose therapy with etoposide, ifosfamide and cisplatin for patients with germ cell tumors.
    Mardiak J; Fuchsberger P; Lakota J; Sálek T; Sycová-Milá Z; Drahokoupilová M; Baláz M; Koza I
    Neoplasma; 2000; 47(4):239-43. PubMed ID: 11043829
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dexamethasone, etoposide, ifosfamide, and cisplatin as second-line therapy in patients with aggressive non-Hodgkin's lymphoma.
    Haim N; Ben-Shahar M; Faraggi D; Tsuri-Etzioni A; Leviov M; Epelbaum R
    Cancer; 1997 Nov; 80(10):1989-96. PubMed ID: 9366303
    [TBL] [Abstract][Full Text] [Related]  

  • 35. VIP (etoposide, ifosfamide and cisplatinum) as a salvage intensification program in relapsed or refractory Hodgkin's disease.
    Ribrag V; Nasr F; Bouhris JH; Bosq J; Brault P; Girinsky T; Cosset JM; Munck JN; Corti C; Decaudin D; Pico JL; Hayat M; Carde P
    Bone Marrow Transplant; 1998 May; 21(10):969-74. PubMed ID: 9632268
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase I study of high-dose cisplatin, ifosfamide, and etoposide.
    Perez EA; Sowray PC; Gardner SL; Gandara DR
    Cancer Chemother Pharmacol; 1994; 34(4):331-4. PubMed ID: 8033300
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combination therapy with carboplatin/cisplatin/ifosfamide/etoposide in ovarian cancer.
    Lund B; Hansen OP; Hansen HH; Hansen M
    Semin Oncol; 1992 Feb; 19(1 Suppl 1):26-9. PubMed ID: 1411618
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cisplatin/etoposide versus ifosfamide/etoposide combination chemotherapy in small-cell lung cancer: a multicenter German randomized trial.
    Wolf M; Havemann K; Holle R; Gropp C; Drings P; Hans K; Schroeder M; Heim M; Dommes M; Mende S
    J Clin Oncol; 1987 Dec; 5(12):1880-9. PubMed ID: 2824710
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cisplatin, etoposide, and ifosfamide salvage therapy for refractory or relapsing germ cell carcinoma.
    Harstrick A; Schmoll HJ; Wilke H; Köhne-Wömpner CH; Stahl M; Schöber C; Casper J; Bruderek L; Schmoll E; Bokemeyer C
    J Clin Oncol; 1991 Sep; 9(9):1549-55. PubMed ID: 1651992
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A phase II trial of mesna/ifosfamide, mitoxantrone and etoposide for refractory lymphomas.
    Rodriguez MA; Cabanillas FC; Hagemeister FB; McLaughlin P; Romaguera JE; Swan F; Velasquez W
    Ann Oncol; 1995 Jul; 6(6):609-11. PubMed ID: 8573542
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.